Gene · 624
BDKRB2: bradykinin receptor B2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. BDKRB2: bradykinin receptor B2. Genes, record 624. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/624
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P30411 | B2 bradykinin receptor | 391 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents70
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026062654 A | 2026-04-10 | 21 | P30411 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39084 | P30411 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 39087 | P30411 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 16652 | P30411 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 20569 | P30411 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 574 | P30411 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 574 | P30411 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 20569 | P30411 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 16652 | P30411 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 9409 | P30411 | Espacenet |
1 to 10 of 70
See all 70 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ANATIBANT | CHEMBL2107725 | Bradykinin B2 receptor antagonist | ANTAGONIST | ChEMBL |
| FASITIBANT | CHEMBL218427 | Bradykinin B2 receptor antagonist | ANTAGONIST | ChEMBL |
| FASITIBANT CHLORIDE | CHEMBL541758 | Bradykinin B2 receptor antagonist | ANTAGONIST | ChEMBL |
| ICATIBANT | CHEMBL2028850 | Bradykinin B2 receptor antagonist | ANTAGONIST | ChEMBL |
| ICATIBANT ACETATE | CHEMBL2028852 | Bradykinin B2 receptor antagonist | ANTAGONIST | ChEMBL |
| LABRADIMIL | CHEMBL2105864 | Bradykinin B2 receptor agonist | AGONIST | ChEMBL |
Trials25
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05509569 | ICATIBANT | ClinicalTrials.gov | ||
| NCT05407597 | ICATIBANT | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT04978051 | ICATIBANT | PHASE2 | ClinicalTrials.gov | |
| NCT04654351 | ICATIBANT | PHASE3 | 2022-03-29 | ClinicalTrials.gov |
| NCT04488081 | ICATIBANT | PHASE2 | ClinicalTrials.gov | |
| NCT04057131 | ICATIBANT ACETATE | 2025-02-21 | ClinicalTrials.gov | |
| NCT03888755 | ICATIBANT | PHASE3 | 2019-08-08 | ClinicalTrials.gov |
| NCT03177798 | ICATIBANT | PHASE2 | 2019-10-29 | ClinicalTrials.gov |
| NCT03005184 | ICATIBANT | PHASE2 | ClinicalTrials.gov | |
| NCT02205814 | FASITIBANT | PHASE2 | 2015-09-16 | ClinicalTrials.gov |
1 to 10 of 25
See all 25 trialsNIH grants1,649
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BDKRB2 papers | Newest fiscal year |
|---|---|---|---|
| T32GM007569 | Clinical Pharmacology Training Program | 9 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| R01DA008863 | Regulation Of Opioid Receptor Signaling by Endogenous Peptides | 5 | 2025 |
| R01HL049277 | Animal Models for Studying the Genetics of Complex Diseases | 5 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
| P30DK036836 | Diabetes Research Center | 4 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 3 | 2025 |
| P30ES013508 | Center of Excellence in Environmental Toxicology | 3 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 3 | 2025 |
| P50HD027802 | Differential Diagnosis in Learning Disabilities | 3 | 2025 |
1 to 10 of 1,649Source NIH's project files
See all 1,649 nih grantsPapers3,739
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mapping Pharmacogenomic Determinants of Adverse Drug Reactions in Hypertension: A Systematic Review. | Pharmaceuticals (Basel) | 2026 | 42797533 | PubTator, text mining | PubMed |
| Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine. | Histopathology | 2026 | 42549509 | PubTator, text mining | PubMed |
| G protein signaling capabilities at the bradykinin 2 receptor. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42547588 | PubTator, text mining | PubMed |
| Pharmacological Characterization of Vasomotor Responses in the Tree Shrew (Tupaia belangeri) Basilar Artery: A Promising Model for Human Cerebrovascular Research. | Biology (Basel) | 2026 | 42510693 | PubTator, text mining | PubMed |
| Overactivated bradykinin-B2 receptor promotes type a aortic dissection by inducing endothelial dysfunction: Therapeutic effect of icatibant. | Life Sci | 2026 | 42413717 | PubTator, text mining | PubMed |
| The bradykinin B2 receptor as a context-dependent modulator of neural circuit function. | Front Cell Neurosci | 2026 | 42211761 | PubTator, text mining | PubMed |
| Molecular mechanisms for subtype selectivity of kinin receptors' antagonists. | Nat Commun | 2026 | 42185275 | PubTator, text mining | PubMed |
| Can Scorpion Venom Peptides Be Safely Used in Cardiovascular Therapy: A Systematic Review. | Cureus | 2026 | 42037951 | PubTator, text mining | PubMed |
| An Immunomodulating Peptide With Potential to Counteract Endometriosis. | Aust N Z J Obstet Gynaecol | 2026 | 41913689 | PubTator, text mining | PubMed |
| The Gut Metabolite Phenylacetylglutamine Inhibits the Angiogenic Potential of Human Umbilical Vein Endothelial Cells Via the β-Adrenergic Receptor-LDHA Axis. | J Cardiovasc Transl Res | 2026 | 41874920 | PubTator, text mining | PubMed |
1 to 10 of 3,739
See all 3,739 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/624
GET https://conductscience.org/api/genes/v1/624/patents?page=2